Litcius/Paper detail

Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

Surya P. Bhatt, Klaus F. Rabe, Nicola A. Hanania, Claus Vogelmeier, Mona Bafadhel, Stephanie A. Christenson, Alberto Papi, Dave Singh, Elizabeth Laws, Paula Dakin, Jennifer Maloney, Xin Lu, Deborah Bauer, Ashish Bansal, Raolat M. Abdulai, Lacey B. Robinson

2025The Lancet Respiratory Medicine65 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboDupilumabPulmonary diseaseInternal medicineDouble blindInflammationRandomized controlled trialPhysical therapyPathologyAlternative medicineAsthmaChronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseasesPediatric health and respiratory diseases
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials | Litcius